Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
82 Results for "
CDK8
" in MedChemExpress (MCE) Product Catalog:
Products (82)
82 Results for "CDK8" in MCE Product Catalog:
Cat. No.: HY-111465R
CAS No.: 1613638-82-6
Target:
Research Areas:
CDK8-IN-4 (Standard) is the analytical standard of CDK8-IN-4 (HY-111465). This product is intended for research and analytical applications. CDK8-IN-4 is an inhibitor of CDK8 extracted from patent WO2014090692A1, compound example 16, with an IC50 of 0.2 nM.
Cat. No.: HY-184727
Target:
Research Areas:
CDK8/BRD4-IN-1 is a dual CDK8/BRD4 inhibitor, with an IC50 of 5.44 μM against CDK8 and an IC50 of 4.03 μM against BRD4. CDK8/BRD4-IN-1 exhibits anticancer activity against colorectal cancer. CDK8/BRD4-IN-1 can be used for the research of colorectal cancer .
Cat. No.: HY-180124
CDK8-IN-20 (Compound 67j) is a selective, potent and orally active type I CDK8 inhibitor with an IC50 of 70.5 nM. CDK8-IN-20 shows IC50 values of 147.8, 726.9 and 217.4 nM for homologous kinase CDK19, CDK7 and CDK9. CDK8-IN-20 can inhibit the Wnt/β-catenin pathway and downregulate the expression of β-catenin, Cyclin D1, and c-Myc. CDK8-IN-20 can induce ROS production and cause G2/M and S phase arrest. CDK8-IN-20can be used for the research of cancer, such as colon cancer .
Cat. No.: HY-111427R
CAS No.: 1818427-07-4
Target:
Research Areas:
CDK8/19-IN-1 (Standard) is the analytical standard of CDK8/19-IN-1 (HY-111427). This product is intended for research and analytical applications. CDK8/19-IN-1 is a potent, selective and oral bioavailable CDK8/19 dual inhibitor, with IC50s of 0.46 nM, 0.99 nM and 270 nM for CDK8, CDK19 and CDK9, respectively.
Cat. No.: HY-P702941
Purity: ≥ 80%, as determined by reducing SDS-PAGE.
Synonyms: CDK8; Cell Division Protein Kinase 8; Cyclin Dependent Kinase 8; Mediator Complex Subunit CDK8; Cyclin-Dependent Kinase 8; Protein Kinase K35; K35; CDK8 Protein Kinase; Mediator Of RNA Polymerase II Transcription Subunit CDK8; IDDHBA
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P703557
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CDK8; Cell Division Protein Kinase 8; Cyclin Dependent Kinase 8; Mediator Complex Subunit CDK8; Cyclin-Dependent Kinase 8; Protein Kinase K35; K35; CDK8 Protein Kinase; Mediator Of RNA Polymerase II Transcription Subunit CDK8; IDDHBA
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P702923
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: CDK8; Cell Division Protein Kinase 8; Cyclin Dependent Kinase 8; Mediator Complex Subunit CDK8; Cyclin-Dependent Kinase 8; Protein Kinase K35; K35; CDK8 Protein Kinase; Mediator Of RNA Polymerase II Transcription Subunit CDK8; IDDHBA; CCNC; SRB11 Homolog
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-101800R
CAS No.: 1449228-40-3
Synonyms: SNX2-1-165 (Standard); BCD-115 (Standard)
Target:
Research Areas:
Senexin B (Standard) (SNX2-1-165 (Standard)) is the analytical standard of Senexin B (HY-101800). This product is intended for research and analytical applications. Senexin B (SNX2-1-165; BCD-115) is a potent, highly water-soluble and bioavailable CDK8/19 inhibitor, with Kds of 140 nM for CDK8 and 80 nM for CDK19.
Cat. No.: HY-111388AR
CAS No.: 2443816-41-7
Synonyms: SEL120-34A monohydrochloride (Standard)
Target:
Research Areas:
Romaciclib monohydrochloride (Standard) is the analytical standard of Romaciclib (monohydrochloride) (HY-111388A). This product is intended for research and analytical applications. SEL120-34A monohydrochloride is an ATP-competitive and selective CDK8 inhibitor, inhibits Kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50s of 4.4 nM and 10.4 nM, respectively, with a Kd of 3 nM for CDK8. SEL120-34A monohydrochloride weakly inhibits CDK9 (calculated IC50=1070 nM), but shows no obvious activity against CDK1, 2, 4, 6, 5, 7. SEL120-34A monohydrochloride inhibits phosphorylation of STAT1 S727 and STAT5 S726 . Has anti-tumor activity .
Cat. No.: HY-RS23525
Target:
Research Areas:
Nedd8 Rat Pre-designed siRNA Set A contains three designed siRNAs for Nedd8 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-111518R
CAS No.: 2209085-22-1
Target:
Research Areas:
JH-XI-10-02 (Standard) is the analytical standard of JH-XI-10-02 (HY-111518). This product is intended for research and analytical applications. JH-XI-10-02 is a PROTAC connected by ligands for Cereblon and CDK. JH-XI-10-02 is a highly potent and selective PROTAC CDK8 degrader, with an IC50 of 159 nM. JH-XI-10-02 causes proteasomal degradation, does not affect CDK8 mRNA levels. JH-XI-10-02 shows no effect on CDK19 .
Cat. No.: HY-187688
SW393109 is a CDK8 inhibitor with an IC50 of 3.16 nM and an EC50 of 5 nM against the DKK1 reporter gene. SW393109 inhibits IFNγ-induced phosphorylation of STAT1 S727, impairs the EWSR1::FLI1 transcriptional program in Ewing sarcoma cells and suppresses tumor cell proliferation. SW393109 acts as a gain-of-function molecular trap that induces the retention of the CDK8 kinase module (CKM) and Mediator complex on chromatin. SW393109 can be used in studies related to Ewing sarcoma .
Cat. No.: HY-183074
Target:
Research Areas:
RO8323 is an orally active, selective CDK8/CDK19 inhibitor, with an IC50 of 2 nM against CDK8 and 3 nM against CDK19. RO8323 promotes regulatory T cell differentiation, inhibits effector T cell generation, reverses the Teff/Treg ratio, upregulates IL-10 production in myeloid cells, and suppresses the production of TNF-α, IL-6 and IL-12. RO8323 enhances immune reconstitution and prolongs cardiac allograft survival in a dose-dependent manner. RO8323 can be used in the research of chronic graft-versus-host disease, cardiac allograft rejection, acute graft-versus-host disease and experimental autoimmune encephalomyelitis .
Cat. No.: HY-126675G
CAS No.: 2241300-51-4
Cat. No.: HY-183423
CAS No.: 2271348-04-8
Target:
Research Areas:
MK256 is an orally active, selective CDK8 inhibitor and CDK19/cyclin C inhibitor with IC50 values of 2.5 nM and 3.3 nM, respectively. MK256 downregulates phosphorylated STAT1 (S727), STAT5 (S726), MCL-1 mRNA and CCL2 mRNA. MK256 exhibits anti-tumor activity in acute myeloid leukemia. MK256 can be used for the research of acute myeloid leukemia .
Cat. No.: HY-145121R
CAS No.: 2871872-79-4
Research Areas:
DS96432529 (Standard) is the analytical standard of DS96432529 (HY-145121). This product is intended for research and analytical applications. DS96432529 is an orally active CDK8 inhibitor with an IC50 of 33 nM. DS96432529 enhances ALPase activity, with an EC200 of 63 nM. DS96432529 inhibits TNF-α-induced activation of the RLR signaling pathway, activates mitophagy, accelerates mineralized nodule formation, and suppresses the proliferation of periodontal ligament stem cells. DS96432529 promotes bone formation, alleviates ligation-induced alveolar bone loss, and increases bone mineral density in ovariectomized animal models. DS96432529 can be used in studies related to periodontitis and osteoporosis .
Cat. No.: HY-187035
CAS No.: 868066-26-6
SNX631 is an orally active and selective CDK8/CDK19 inhibitor. SNX631 reduces the phosphorylation of STAT1/STAT3 S727, and upregulates miR-21-5p, miR-21-3p and miR-221 in cancer cells. SNX631 transcription-independently inhibits meiotic resumption in mouse oocytes, blocks nuclear envelope breakdown, first polar body extrusion and mitochondrial expansion and aggregation, with no cytotoxicity. SNX631, in combination with Lapatinib (HY-50898) or Trastuzumab (HY-P9907), synergistically inhibits cancer cell growth, upregulates the tumor suppressor BTG2, prevents Lapatinib-induced upregulation of oncogenic miRNAs, overcomes drug resistance, reduces the infiltration of αSMA+ stromal fibroblasts and ARG1+ M2 macrophages, and exhibits favorable biosafety. SNX631 can be used in studies related to HER2-positive breast cancer and cancer .
Cat. No.: HY-102069R
CAS No.: 956025-83-5
Research Areas:
3MB-PP1 (Standard) is the analytical standard of 3MB-PP1 (HY-102069). This product is intended for research and analytical applications. 3MB-PP1, a bulky purine analog, is a Polo-like kinase 1 (Plk1) inhibitor. 3MB-PP1 blocks mitotic progression and cell division arise through target Plk1 in in cells expressing analog-sensitive Plk1 alleles. 3MB-PP1 specifically inhibits the activity of analog-sensitive Ssn3 (Cdk8). 3MB-PP1 inhibits Leu93 Mutant Zipper-interacting protein kinase (Leu93-ZIPK; IC50=2 μM). 3MB-PP1 can be used for the research of hypha formation of Candida albicans and cell division .
Cat. No.: HY-P701363
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: CDK19; Cell Division Protein Kinase 19; Prev. CDC2L6; Cyclin-Dependent Kinase 19; Prev. CDK11; Cyclin-Dependent Kinase 11; BA346C16.3; Death-Preventing Kinase; KIAA1028; CDK8-Like Cyclin-Dependent Kinase; Cell Division Cycle 2-Like Protein Kinase 6; Cycli
Species:
Human
Source:
Sf9 insect cells
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
